BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
0.1922
+0.0033 (1.75%)
At close: May 15, 2026, 4:00 PM EDT
0.1978
+0.0056 (2.91%)
After-hours: May 15, 2026, 6:58 PM EDT
BioRestorative Therapies Revenue
BioRestorative Therapies had revenue of $23.17K in the quarter ending March 31, 2026, a decrease of -7.32%. This brings the company's revenue in the last twelve months to $357.87K, down -8.47% year-over-year. In the year 2025, BioRestorative Therapies had annual revenue of $359.70K, down -10.30%.
Revenue (ttm)
$357.87K
Revenue Growth
-8.47%
P/S Ratio
13.68
Revenue / Employee
$25,562
Employees
14
Market Cap
4.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 359.70K | -41.30K | -10.30% |
| Dec 31, 2024 | 401.00K | 255.20K | 175.03% |
| Dec 31, 2023 | 145.80K | 26.00K | 21.70% |
| Dec 31, 2022 | 119.80K | 73.80K | 160.43% |
| Dec 31, 2021 | 46.00K | -31.00K | -40.26% |
| Dec 31, 2020 | 77.00K | -53.00K | -40.77% |
| Dec 31, 2019 | 130.00K | 19.00K | 17.12% |
| Dec 31, 2018 | 111.00K | 30.00K | 37.04% |
| Dec 31, 2017 | 81.00K | 44.65K | 122.80% |
| Dec 31, 2016 | 36.36K | -592.56K | -94.22% |
| Dec 31, 2015 | 628.92K | 212.92K | 51.18% |
| Dec 31, 2014 | 416.00K | 414.32K | 24,661.67% |
| Dec 31, 2013 | 1.68K | -13.91K | -89.22% |
| Dec 31, 2012 | 15.59K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBRTX News
- 2 days ago - BioRestorative Therapies presents preclinical data on MSC exosome proteomics - TheFly
- 3 days ago - BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals - GlobeNewsWire
- 8 days ago - BioRestorative Therapies reports expanded Phase 2 blinded dataset for BRTX-100 - TheFly
- 8 days ago - BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease - GlobeNewsWire
- 16 days ago - BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform - GlobeNewsWire
- 25 days ago - BioRestorative Therapies announces partnership with David Goldberg, M.D. - TheFly
- 25 days ago - BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform - GlobeNewsWire
- 5 weeks ago - BioRestorative Therapies announces strategic collaboration with 203 Creates - TheFly